Online Registration: While walk-ins are always welcomed, advance registration is appreciated – please note: the charge for all walk-ins in $15

Description

CAR-T therapy, where white blood cells are re-engineered to attach cancer cells, is an extremely promising new approach to treating cancer. However, the high cost the therapy ($380-475K) will likely limit the accessibility of this promising therapy. Draper believes that costs can be significantly reduced and patient access expanded by simplifying the manufacturing process and bringing it closer to the patient. The talk will discuss the complexity of the current process, the market and regulatory challenges of bringing it closer to the patient and the potential solutions to resolve these issues.

Location

100 Cummings Center, Suite 221-E
Beverly MA USA

Date and Time

Begins: 03/02/2018 12:30 PM
Ends: 03/02/2018 02:00 PM

Speaker: David O’Dowd

David O’Dowd is an Associate Director in the Biomedical Solutions group at Draper Laboratory where he has focused on identifying technologies developed at Draper which have potential to address significant clinical unmet need with a strong business case. Prior to joining Draper, Mr. O’Dowd was Director of Life Sciences at Forge Partners, a boutique early stage investment company from 2007-2008 and led the company’s life science investment identification and evaluation. From 2002 – 2007, he was Managing Director of DGO Consulting, providing strategic consulting services to early-stage life science companies. From 2001 to 2002 he was Vice President of Business Development and Strategy at PrivaSource, Inc, which was focused on healthcare data aggregation and de-identification. From 1997 to 2001 he was Director of Development and Director of Marketing at Genomics Collaborative, a genomics start-up that built a repository of 100,000 DNA and tissue samples with detailed medical information from people around the world with common diseases. From 1992 until 1997, he was Manager at Health Advances, a healthcare-focused strategy consulting firm.

Mr. O’Dowd holds a B.S. in Chemical Engineering from the University of Rochester and an S.M. in Technology and Policy from MIT.

Our Hosts: Landiorio, Teska & Coleman, LLP

In today’s dynamic business world of global competition and international markets, when a new product, idea, or service is created, the chances are great that someone will imitate it.

The only way an innovator can stop an imitator is through intellectual property rights.

To learn more, visit our website at www.iandiorio.com

Networking/Lunch

Registration, networking and lunch start at 12:30; Program
begins at 1 p.m.